← Back to patent-cliff list
LY-2940094
Tier C — Watch / tradeLY-2940094
Eli Lilly and Company
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：OOR
Indications (approved)：Major depressive disorder, Anxiety disorder, Anxiety, 心理压力, Parkinson's disease, 运动障碍, Alcohol abuse
Regional status
US
Phase II
2012-11-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LY-2940094?
Approved indications include: Major depressive disorder, Anxiety disorder, Anxiety, 心理压力, Parkinson's disease, 运动障碍, Alcohol abuse.
When does the LY-2940094 patent expire?
No public expiry year is available for LY-2940094 yet; this page updates once verified.
How do I get a quote for LY-2940094 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-13